IP Verse

Deva Holding competitive analysis

Latest oppositions filed by Deva Holding

Explore patent oppositions filed by Deva Holding against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 6, 2026
Patent NumberTitleApplicantOpposition Date
EP3858859
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 28, 2026
EP4188389
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAJun 11, 2026
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEMay 13, 2026
EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 28, 2026
EP3377534
Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 AntibodyBRISTOL MYERS SQUIBBMar 11, 2026
EP4338805
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026
EP4342546
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026
EP4218732
Tablets Comprising Eltrombopag OlamineNOVARTISDec 16, 2025
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 22, 2025

Latest PTAB cases involving Deva Holding

Discover the latest PTAB cases involving Deva Holding, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Deva Holding with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 6, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DEVA HOLDING3 - - -
AMGEN EUROPE240 - -
BRISTOL MYERS SQUIBB - 90 - 8
NOVO NORDISK912819